Home › Companies › Structure Therapeutics Inc. › 2025-2026

Structure Therapeutics Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Structure Therapeutics Inc.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 04 October 2026.

5Ballot items
211Asset managers
906Fund votes
2026-06-17Meeting date

Proxy season: 2024-2025 2025-2026

Explore Structure Therapeutics Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Structure Therapeutics Inc.

These tallies are Structure Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Structure Therapeutics Inc. — official shareholder meeting results, meeting held 2026-06-17
Ballot item	For	Against	Abstain	Withheld	Outcome
Elect Director: Ted W. Love, M.D.	164,241,780	533,358	172,641	--	Majority: yes
Elect Director: Raymond Stevens, Ph.D.	164,373,741	400,929	173,109	--	Majority: yes
Elect Director: Daniel G. Welch	161,336,058	3,429,342	182,379	--	Majority: yes
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's shareholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered	164,767,215	20,784	159,780	--	Majority: yes
Proposal 3: Advisory vote on the compensation of the Company's named executive officers On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Gen	158,547,441	6,187,647	212,691	--	Majority: yes

Source: Structure Therapeutics Inc., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.

How asset managers voted at the Structure Therapeutics Inc. 2025-2026 meeting

Each item below shows how the 211 asset managers that disclosed a Structure Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 158,547,441AGAINST: 6,187,647

Structure Therapeutics Inc.’s own tally for this item (“Proposal 3: Advisory vote on the compensation of the Company's named executive officers On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Comp”): 158,547,441 for, 6,187,647 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 213,208,000 outstanding shares: 74% for, 3% against (77% of the company cast a for/against vote).

The 210 asset managers below cast 96% of the shares they voted on this item FOR (72,142,589 for, 3,177,092 against).

FOR 96%

FOR: 72,142,589 (95.8%)AGAINST: 3,177,092 (4.2%)ABSTAIN: 10,973 (0.0%)NOT VOTED: 196 (0.0%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at Structure Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	14,914,770	0	For
Janus Henderson	10,284,405	0	For
Wellington	6,361,518	0	For
Avoro Capital Advisors LLC	5,140,724	0	For
Deep Track Capital, LP	4,079,848	0	For
T. Rowe Price	3,531,224	0	For
Vanguard	3,486,786	0	For
BVF INC/IL	3,459,358	0	For
American Century	0	2,910,731	Against
JANUS INVESTMENT FUND	1,588,256	0	For
PRINCIPAL GLOBAL INVESTORS	1,521,568	0	For
ORBIMED ADVISORS LLC	1,475,403	0	For
Siren, L.L.C.	1,293,423	0	For
Principal	1,269,498	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	1,053,047	0	For
Casdin Capital, LLC	906,363	0	For
AllianceBernstein	887,569	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	874,000	0	For
Logos Global Management LP	787,068	0	For
PERMANENT PORTFOLIO FAMILY OF FUNDS	750,000	0	For
Paradigm Biocapital Advisors LP	734,522	0	For
Rock Springs Capital Management LP	640,230	0	For
FRANKLIN ADVISERS INC	571,710	0	For
Hartford	452,642	0	For
Aberdeen	391,809	0	For

Showing the 25 largest of 210 asset managers. See all 210 in the interactive database.

2. Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Daniel G. Welch

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 161,336,058AGAINST: 3,429,342

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Daniel G. Welch”): 161,336,058 for, 3,429,342 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 213,208,000 outstanding shares: 76% for, 2% against (77% of the company cast a for/against vote).

The 55 asset managers below cast 97% of the shares they voted on this item FOR (19,574,137 for, 576,006 against).

FOR 97%

FOR: 19,574,137 (97.1%)AGAINST: 576,006 (2.9%)ABSTAIN: 10,973 (0.1%)

Largest asset managers voting on “Election of the nominees for Class III director named below to hold office until the 2029 annual general meeti” at Structure Therapeutics Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	6,884,730	0	0	For
Vanguard	3,486,441	0	0	For
JANUS INVESTMENT FUND	1,588,256	0	0	For
T. Rowe Price	1,563,084	0	0	For
American Century	1,378,553	0	0	For
Principal	1,221,000	48,498	0	For
PERMANENT PORTFOLIO FAMILY OF FUNDS	750,000	0	0	For
Hartford	452,642	0	0	For
BlackRock	325,867	0	0	For
FRANKLIN STRATEGIC SERIES	321,647	0	0	For
John Hancock	270,075	0	0	For
DRIEHAUS MUTUAL FUNDS	216,484	0	0	For
AllianceBernstein	0	212,692	0	Against
AB DISCOVERY GROWTH FUND, INC.	0	161,888	0	Against
Bridge Builder Trust	147,713	0	0	For
Equitable	31,604	62,568	0	Against
AIG/SunAmerica	82,205	0	0	For
Lincoln Financial	80,497	0	0	For
OPTIMUM FUND TRUST	76,015	0	0	For
Delaware/Macquarie	0	58,000	0	Against
ALPS ETF Trust	56,911	0	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	49,504	0	0	For
Northwestern Mutual	47,654	0	0	For
Brighthouse	33,412	0	10,973	For
Allspring	43,171	0	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

3. Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Raymond Stevens, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 164,373,741AGAINST: 400,929

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Raymond Stevens, Ph.D.”): 164,373,741 for, 400,929 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 213,208,000 outstanding shares: 77% for, 0.2% against (77% of the company cast a for/against vote).

The 55 asset managers below cast 100% of the shares they voted on this item FOR (20,150,143 for, 0 against).

FOR 99.9%

FOR: 20,150,143 (99.9%)ABSTAIN: 10,973 (0.1%)

Largest asset managers voting on “Election of the nominees for Class III director named below to hold office until the 2029 annual general meeti” at Structure Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	6,884,730	0	For
Vanguard	3,486,441	0	For
JANUS INVESTMENT FUND	1,588,256	0	For
T. Rowe Price	1,563,084	0	For
American Century	1,378,553	0	For
Principal	1,269,498	0	For
PERMANENT PORTFOLIO FAMILY OF FUNDS	750,000	0	For
Hartford	452,642	0	For
BlackRock	325,867	0	For
FRANKLIN STRATEGIC SERIES	321,647	0	For
John Hancock	270,075	0	For
DRIEHAUS MUTUAL FUNDS	216,484	0	For
AllianceBernstein	212,692	0	For
AB DISCOVERY GROWTH FUND, INC.	161,888	0	For
Bridge Builder Trust	147,713	0	For
Equitable	94,172	0	For
AIG/SunAmerica	82,205	0	For
Lincoln Financial	80,497	0	For
OPTIMUM FUND TRUST	76,015	0	For
Delaware/Macquarie	58,000	0	For
ALPS ETF Trust	56,911	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	49,504	0	For
Northwestern Mutual	47,654	0	For
Brighthouse	33,412	10,973	For
Allspring	43,171	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

4. Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Ted W. Love, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 164,241,780AGAINST: 533,358

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Ted W. Love, M.D.”): 164,241,780 for, 533,358 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 213,208,000 outstanding shares: 77% for, 0.3% against (77% of the company cast a for/against vote).

The 55 asset managers below cast 100% of the shares they voted on this item FOR (20,150,143 for, 0 against).

FOR 99.9%

FOR: 20,150,143 (99.9%)ABSTAIN: 10,973 (0.1%)

Largest asset managers voting on “Election of the nominees for Class III director named below to hold office until the 2029 annual general meeti” at Structure Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	6,884,730	0	For
Vanguard	3,486,441	0	For
JANUS INVESTMENT FUND	1,588,256	0	For
T. Rowe Price	1,563,084	0	For
American Century	1,378,553	0	For
Principal	1,269,498	0	For
PERMANENT PORTFOLIO FAMILY OF FUNDS	750,000	0	For
Hartford	452,642	0	For
BlackRock	325,867	0	For
FRANKLIN STRATEGIC SERIES	321,647	0	For
John Hancock	270,075	0	For
DRIEHAUS MUTUAL FUNDS	216,484	0	For
AllianceBernstein	212,692	0	For
AB DISCOVERY GROWTH FUND, INC.	161,888	0	For
Bridge Builder Trust	147,713	0	For
Equitable	94,172	0	For
AIG/SunAmerica	82,205	0	For
Lincoln Financial	80,497	0	For
OPTIMUM FUND TRUST	76,015	0	For
Delaware/Macquarie	58,000	0	For
ALPS ETF Trust	56,911	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	49,504	0	For
Northwestern Mutual	47,654	0	For
Brighthouse	33,412	10,973	For
Allspring	43,171	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

5. To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 164,767,215AGAINST: 20,784

Structure Therapeutics Inc.’s own tally for this item (“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's shareholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 164,767,215 for, 20,784 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 213,208,000 outstanding shares: 77% for, 0.1% against (77% of the company cast a for/against vote).

The 55 asset managers below cast 100% of the shares they voted on this item FOR (20,150,143 for, 0 against).

FOR 99.9%

FOR: 20,150,143 (99.9%)ABSTAIN: 10,973 (0.1%)

Largest asset managers voting on “To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company” at Structure Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	6,884,730	0	For
Vanguard	3,486,441	0	For
JANUS INVESTMENT FUND	1,588,256	0	For
T. Rowe Price	1,563,084	0	For
American Century	1,378,553	0	For
Principal	1,269,498	0	For
PERMANENT PORTFOLIO FAMILY OF FUNDS	750,000	0	For
Hartford	452,642	0	For
BlackRock	325,867	0	For
FRANKLIN STRATEGIC SERIES	321,647	0	For
John Hancock	270,075	0	For
DRIEHAUS MUTUAL FUNDS	216,484	0	For
AllianceBernstein	212,692	0	For
AB DISCOVERY GROWTH FUND, INC.	161,888	0	For
Bridge Builder Trust	147,713	0	For
Equitable	94,172	0	For
AIG/SunAmerica	82,205	0	For
Lincoln Financial	80,497	0	For
OPTIMUM FUND TRUST	76,015	0	For
Delaware/Macquarie	58,000	0	For
ALPS ETF Trust	56,911	0	For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC	49,504	0	For
Northwestern Mutual	47,654	0	For
Brighthouse	33,412	10,973	For
Allspring	43,171	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Largest Structure Therapeutics Inc. shareholders voting in 2025-2026

Ranked by the number of Structure Therapeutics Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 213,208,000 shares outstanding at the time of that meeting.

Top Structure Therapeutics Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	7.00%
2	Janus Henderson	4.82%
3	Wellington	2.98%
4	Avoro Capital Advisors LLC	2.41%
5	Deep Track Capital, LP	1.91%
6	T. Rowe Price	1.66%
7	Vanguard	1.64%
8	BVF INC/IL	1.62%
9	American Century	1.37%
10	JANUS INVESTMENT FUND	0.74%

Reported Structure Therapeutics Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Structure Therapeutics Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Entities affiliated with FMR LLC	14.59%	DEF14A
Entities affiliated with Wellington Management Group LLP	10.02%	DEF14A
Entities affiliated with Avoro Capital Advisors LLC	9.77%	DEF14A
Entities affiliated with Janus Henderson Group plc	6.26%	DEF14A
Deep Track Capital, LP	5.79%	13G
Entities affiliated with Deep Track Capital, LP	5.79%	DEF14A
BVF PARTNERS L P/IL	4.90%	13G
FMR (Fidelity)	3.94%	13F
Wellington Management	3.41%	13F
Raymond Stevens, Ph.D.	2.16%	DEF14A

Percentages above are of 213,208,000 shares outstanding, as reported by Structure Therapeutics Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Structure Therapeutics Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Structure Therapeutics Inc.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 211 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 906 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Structure Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.

Structure Therapeutics Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).